6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy.

      European Heart Journal

      Adolescent, Adrenergic beta-Antagonists, therapeutic use, Adult, Age Distribution, Age Factors, Androgens, metabolism, Cardiomyopathy, Hypertrophic, drug therapy, mortality, Child, Cohort Studies, Death, Sudden, Cardiac, epidemiology, etiology, Electrocardiography, Female, Humans, Male, Practice Guidelines as Topic, Risk Assessment, Sex Factors, Ventricular Outflow Obstruction

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hypertrophic cardiomyopathy (HCM) is the commonest inherited cause of sudden cardiac death in children; current guidelines suggest HCM screening after 12-15 years of age. The study aims to establish the age range at highest risk. Cohort study from six regional centres of paediatric cardiology, including children presenting with sudden death; n = 150 (59% = male; 39% familial HCM). Age- and gender-specific mortality was calculated, and compared with rates calculated from the Swedish National Cause of Death Registry. There were 56 deaths within the cohort, 39 were sudden arrhythmia deaths, with 31 at <19 years of age. Between 9-13.9 years of age annual sudden death mortality averages 7.2%, vs. 1.7% after 16 years of age; P = 0.025, odds ratio for proportions 3.75 [95% confidence intervals (CI) 1.18-11.91], similar in both familial and idiopathic HCM. The risk for sudden death peaks earlier in girls (10-11 years), with male preponderance after the age of 15. National cause of death statistics confirm that the mortality rate from HCM is significantly higher in the 8-16 year olds (0.112 per 100,000 age-specific population) than in the 17-30 year olds (0.055 per 100,000; 95% CI 0.011-0.099). In families with HCM, children should be screened at an early age.

          Related collections

          Author and article information

          Journal
          18385119
          10.1093/eurheartj/ehn122

          Comments

          Comment on this article